Cigna takes action on prior auth

The latest stories trending on MedCity News.

Editor's Pick

Top Story Cigna Cuts 25% of Medical Services from Prior Authorization Requirements Cigna removed 25% of medical services from prior authorization requirements. This represents more than 600 codes, and includes 100 surgical codes, nearly 200 genetic testing codes, durable medical equipment, orthoses and prosthetics and other services, said Dr. Scott Josephs, chief medical officer of Cigna Healthcare. Sponsored Content Payer's Place: Carrie Kincaid of Priority Health Presented by HLTH and MedCity News Carrie Kincaid, Senior Vice President of Market Development at Priority Health joins us for this edition of the Payer's Place to discuss how they are addressing the gaps in rural healthcare and the potential closures of hospitals in those areas.  She also highlights the importance of mobile clinics and getting more services covered for their members. Watch the entire interview here.

Featured News

Skin Microbiome and Allergies: Understanding the Role of Microbes in Allergic Skin Conditions Future research should focus on identifying the interactions between the immune system, microbes, and allergic responses; and exploring potential therapeutic strategies targeting the skin microbiome for allergy management. 5 Ways Patient Access Software Solutions Can Transform Mental Health Care By leveraging sophisticated patient intake forms, robust patient-provider matching algorithms, self-scheduling features, calendar management tools, and telehealth capabilities, healthcare providers can bridge the gap between consumer expectations and the current state of healthcare access. The Importance of Continuous Iteration in Health Equity Plans for REACH ACOs Next year REACH ACOs will have to show success in developing and maintaining comprehensive health equity plans, and by kicking the can down the road they risk not knowing enough about their patient population in terms of what works better and what doesn't. ACOs can pay in the effort of continuous iteration now or they can pay in poor health outcomes for their patients and the resulting increased costs. The choice is theirs, but one they each have to make. Rapport Therapeutics Snags $150M to Develop Precision Neurology Meds Rapport Therapeutics, a clinical-stage biotech that was founded last year, raised $150 million in Series B financing, bringing its total funding to date to $250 million. The company's platform leverages receptor-associated proteins to create neurology drugs that have more focused activity in the brain, going after disease-driving circuits and cell types.

Resources

The Future of Healthcare CIOs Learn how successful CIOs are adapting to challenging times and how they might shift their roles in response to exciting innovation in the years to come. Download Now

MedCity News • PO Box 901 • New York, NY unsubscribe